positiveAnecdotalApr 18, 2026
Next-generation GLP-1 anticipation
Retatrutide sentiment is driven by anticipation around phase 3 obesity outcomes and its triple-agonist mechanism.
ClinicalTrials.govhigh confidenceindustry
Source Retatrutide
LY3437943
Weight LossNot ApprovedPhase IIIResearchSubQ
Popular for:Weight loss, triple agonist (GLP-1/GIP/glucagon)
32
Registered Trials
6
Trial Publications
133
PubMed References
Phase III
Evidence Level
Overview
Retatrutide (LY3437943) is a novel triple-hormone receptor agonist developed by Eli Lilly. The short version: people usually care about it for weight loss, triple agonist (glp-1/gip/glucagon), but the strength of the evidence depends heavily on indication and study type.
Retatrutide (LY3437943) is a novel triple-hormone receptor agonist developed by Eli Lilly. It simultaneously activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It represents the most potent weight loss peptide in clinical development, achieving up to 24.2% body weight reduction in Phase 2 trials — exceeding both semaglutide and tirzepatide.
**Originally developed for: **Obesity and type 2 diabetes treatment by Eli Lilly. Also being studied for metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD).
Research Snapshot
What the evidence says
Phase IIIRetatrutide currently shows 32 registered trials from ClinicalTrials.gov, 6 PubMed trial publications (5 RCT-tagged), and 133 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 32 registered trials are tracked from ClinicalTrials.gov intervention records.
- 6 PubMed clinical-trial publications are indexed.
- 5 PubMed randomized controlled trial publications are indexed.
- 133 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
Triple agonism: GLP-1 receptor activation reduces appetite and slows gastric emptying.
Key Research Benefits
Primary Benefits:
Unprecedented weight loss — Up to 24.2% body weight reduction at 48 weeks (NEJM Phase 2 trial, Jastreboff et al., 2023)
Glycemic control — Significant HbA1c reductions in type 2 diabetes patients
Liver fat reduction — Phase 2a MASLD trial showed dramatic liver fat reduction (Nature Medicine, 2024)
Improved lipid profile — Reduces triglycerides, improves cholesterol markers
Secondary Benefits:
Blood pressure reduction
Waist circumference reduction
Potential cardiovascular risk reduction (under investigation)
Clinical Evidence Summary
Research Pipeline
Preclinical
Animal
Phase I
Phase II
Phase III
Approved
32
Registered Trials
6
Trial Publications
5
RCT Publications
133
PubMed References
ClinicalTrials.govPubMed ESearchExact-name queryChecked May 3, 2026
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
32
Registered trials
6
Trial publications
5
RCT publications
133
PubMed references
85
Reviews
13
Meta-analyses
Registered trials source
Jun 1, 2026
Retatrutide
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View source- Jastreboff et al. (2023, NEJM) — Phase 2 trial in obesity. 338 participants. 24.2% weight loss at highest dose (12 mg) over 48 weeks. Published in New England Journal of Medicine.
- Sanyal et al. (2024, Nature Medicine) — Phase 2a MASLD trial. Demonstrated significant liver fat reduction and potential for NASH/MASLD treatment.
- Phase 2 type 2 diabetes trial — Significant HbA1c reductions alongside weight loss.
> Clinical trial status: Phase 3 trials (TRIUMPH program) are ongoing for obesity and type 2 diabetes. Eli Lilly is the sponsor. Expected FDA submission timeline is pending Phase 3 results. This is one of the most anticipated weight loss drugs in the pipeline.
Key PubMed References
133 PubMed references · showing top 25 by relevance
View all on PubMedRetatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
Human Study
Giblin K, Kaplan LM, Somers VK, et al. · Diabetes, obesity & metabolism · 2026
PMID: 41090431Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes.
Review
Olowo-Oribi BA, Salway RJ · Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2025
PMID: 40583149Retatrutide-A Game Changer in Obesity Pharmacotherapy.
Review
Katsi V, Koutsopoulos G, Fragoulis C, et al. · Biomolecules · 2025
PMID: 40563436Emerging pharmacotherapies for obesity: A systematic review.
Meta-Analysis
Kokkorakis M, Chakhtoura M, Rhayem C, et al. · Pharmacological reviews · 2025
PMID: 39952695What is the pipeline for future medications for obesity?
Review
Melson E, Ashraf U, Papamargaritis D, et al. · International journal of obesity (2005) · 2025
PMID: 38302593Anecdotes & Sentiment
Public discussion, not clinical evidence
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
Side Effects & Safety
**Common Side Effects (from Phase 2 trial):** - Nausea (most common — dose-dependent, reduces with titration) - Diarrhea - Vomiting - Constipation - Decreased appetite (intended effect but can be excessive) **Rare but Serious Risks:** - Increased heart rate (small but measurable in trials) - Potential pancreatitis risk (class concern for GLP-1 agonists) - Thyroid C-cell tumor risk (class concern — rodent studies; human relevance unclear) - Gallbladder issues with rapid weight loss > Contraindications: Personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Common Side Effects (from Phase 2 trial):
Nausea (most common — dose-dependent, reduces with titration)
Diarrhea
Vomiting
Constipation
Decreased appetite (intended effect but can be excessive)
Rare but Serious Risks:
Increased heart rate (small but measurable in trials)
Potential pancreatitis risk (class concern for GLP-1 agonists)
Thyroid C-cell tumor risk (class concern — rodent studies; human relevance unclear)
Gallbladder issues with rapid weight loss
> Contraindications: Personal or family history of medullary thyroid carcinoma or MEN2 syndrome. History of pancreatitis. Caution in type 1 diabetes. Drug interactions: Insulin and sulfonylureas (hypoglycemia risk). May affect absorption of oral medications due to delayed gastric emptying.
Known Interactions
No curated interaction entry is live for Retatrutide yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.